Uses of Braicef

Braicef is a drug belonging to the group of antibiotics reserved for use in cases of respiratory infections and urinary tract infections with life-threatening complications. To ensure effective use, users need to follow the instructions of their doctors, and refer to the following article for more information about the uses of Braicef.

Braicef drug has the main ingredient Cefpirom (in the form of a mixture of Cefpirom sulfate and sodium carbonate) with the content of 2000 mg. The drug is recommended for use in children 12 years of age and older and adults. Cefpirom is a new cephalosporin antibiotic with a broad spectrum of activity against Gram-positive and Gram-negative bacteria. Cefpirom is a new antibiotic, so it tends to cause less resistance to Gram-positive bacteria.
Bactericidal spectrum:
Gram-positive pathogenic bacteria such as Staphylococcus epidermidis, Staphylococcus aureus, Staphylococcus saprophyticus and Group A, B, C Streptococci. Important Gram-negative bacteria that are susceptible to cefpirom include Haemophilus influenzae, Proteus, Escherichia coli, Klebsiella and Enterobacter. Enterococcus faecalis has low susceptibility and Pseudomonas aeruginosa has intermediate susceptibility. Bacteroides fragilis, methicillin-resistant Staphylococcus (MRSA) and other Bacteroides are all resistant to cefpirome. Clostridium difficile, Pseudomonas maltophilia and Enterococcus faecium are not susceptible to cefpirom. The drug Braicef with the main ingredient is Cefpirom antibiotic, which is not a preferred antibiotic for initial use, but a reserve antibiotic indicated for use in complicated respiratory and urinary tract infections. Severe, life-threatening, sepsis of urinary or gastrointestinal origin. The drug is used in combination with other antibiotics that are effective against anaerobic bacteria.
The drug is contraindicated in the following cases:
Patients who are allergic to the main ingredient Cefpirom, Cephalosporin group or any ingredient of the drug. Not recommended for use in children < 12 years old.

2.1. How to take Braicef The drug Braicef is administered intravenously. The usual dose and duration of treatment depend on the severity and type of infection and the patient's kidney function.
2.2. Dosage of Braicef The usual dose is 1 to 2 g, every 12 hours. In case of patients with complicated respiratory infections: 2 g, every 12 hours. In case of patients with complicated urinary tract infections: 1 g, every 12 hours. In case of patient with sepsis, or life-threatening infection: 2 g every 12 hours. Patients with renal impairment: In case of creatinine clearance < 50 ml/min, dose adjustment is required. Serum creatinine should not be measured by the Jaffé method (or pitrate) because it will give false results while taking cefpirom (the result is often higher than the correct reading). In general, in an emergency, treatment of Braicef in children is done only when other treatments are not possible. If absolutely necessary, the dose calculation for children will be based on the above doses per kg body weight and prescribed by the doctor.

Before initiating treatment with Braicef, a thorough investigation of the patient's history of allergy to cephalosporins, penicillins or other drugs is required. In the case of a patient with a penicillin allergy, there is a very high risk of cross-allergic reactions causing serious reactions to the cephalosporins. In patients with renal impairment, the dose should be reduced. There is an increased risk of non-renal adverse reactions, if Braicef is used in combination with aminoglycosides (streptomycin, gentamicin....) or Braicef is used with loop diuretics. During treatment as well as after treatment can occur severe and acute diarrhea, when using broad-spectrum antibiotics in general. This could be a symptom of pseudomembranous colitis. In this case, you need to stop taking the medicine and reassess, maybe your doctor will give you the appropriate antibiotic (metronidazole or vancomycin). Do not take medications that cause constipation. Do not use the drug when the vial seal has been opened, the cap is lost, the vial's visual appearance shows that the powder for injection is discolored. Clinical experience in the treatment of pregnant women with cefpirome is limited. Braicef should be considered for this target group. There are currently insufficient data to assess the risk to a nursing infant. Therefore, it is recommended that breast-feeding be discontinued when treatment with Braicef is required. People who need to be careful when using Braicef 2g: the elderly, children under 15 years of age, pregnant women, lactating women, people with liver failure, kidney failure, people who are sensitive to any of these substances. ingredients of the drug... Or subjects with hepatic coma, myasthenia gravis, stomach ulcers.

Common side effects: Inflammation of the vein at the injection site, nausea, diarrhea, increased alkaline phosphatase and transaminases, increased blood creatinine... Uncommon side effects: Headache, fever, allergies , anorexia, injection site irritation, candidiasis, thrombocytopenia, thrombocytosis, eosinophilia, insomnia, dizziness, convulsions. Rare side effects: somnolence, anaphylactic reactions, hemolytic anemia, leukopenia, gastrointestinal disturbances, pseudomembranous colitis....

Probenecid reduces the tubular secretion of cephalosporin antibiotics eliminated by this mechanism, thereby increasing and prolonging Braicef serum concentrations, prolonging elimination half-life and increasing the risk of toxicity. Braicef. There is a potential for nephrotoxicity when cephalosporins are used together with other nephrotoxic drugs, e.g. loop diuretics, especially in patients with pre-existing impaired renal function. Braicef should not be used with bicarbonate solutions.